1223498-69-8|BAY-1000394, developed by Bayer, inhibits CDKs involved in the cell cycle (CDK1, CDK2, CDK3 and CDK4) along with the one implicated in the regulation of transcription (CDK7 and CDK9), with IC50 values ranging from 5 to 25 nM. This compound is in phase I clinical development for various types of tumours. BAY-1000394 studies also shown that it could be efficient in combination with cisplatin . BAY 1000394 clearly overcomes many limitations of other drugs since it displays high solubility in water, even at neutral pH, and low efficacious oral doses. Furthermore, BAY 1000394 has proven antitumor activity in xenograft models resistant to standard drugs such as doxorubicin, cisplatin, or paclitaxel, and has shown its potential for combination treatment with drugs on the market . The full story about this nanomolar pan-CDK inhibitor BAY 1000394, which contains an unusual sulfoximide group, has been recently disclosed.
Copyright © 2014-2016 上海腾渤医药科技有限公司. All Rights Reserved. 沪ICP备15036794
电话：+86 021 5433 8626 传真：+86 021 5433 8626*801 E-mail: firstname.lastname@example.org QQ:3076941958